Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xbrane Biopharma AB

www.xbrane.com

Latest From Xbrane Biopharma AB

Last Year’s Winners Build On Successes

Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.

Generic Drugs Biosimilars

Stada and Xbrane Add Two To Biosimilar Development Alliance

Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.
Deals Biosimilars

Xbrane Expects Its Lucentis Rival To Capture A Quarter Of Volumes

Xbrane, which has just kicked off a Phase III study for its Xlucane ranibizumab biosimilar to Lucentis, has set a target of ranibizumab generating annual sales of €350m within three years of launch, based on capturing a quarter of the Lucentis market by volume in both Europe and the US.

Biosimilars Strategy

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.

M & A Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Xbrane Biopharma AB
  • Senior Management
  • Martin Åmark, CEO
    Susanna Helgesen, CFO
    Siavish Bashiri, COO & Head, Biosimilars
    David Vikström , PhD, CTO
  • Contact Info
  • Xbrane Biopharma AB
    Banvaktsvägen 22
    Solna, 171 48
    Sweden
UsernamePublicRestriction

Register